EE215 Pharmacoeconomic Analysis of Adjuvant Nivolumab for Patients With Resected Esophageal or Gastroesophageal Junction Cancer in Switzerland

Abstract

Switzerland recently approved and reimbursed nivolumab as the first adjuvant treatment for patients with resected esophageal cancer (EC) or gastroesophageal junction cancer (GEJC). A phase 3 randomised controlled trial (CM577) comparing nivolumab with placebo in patients with resected EC or GEJC found that nivolumab was associated with 31% lower risk of recurrence or death and double the median disease-free survival compared with placebo. We evaluated the cost-utility of nivolumab compared with placebo from a Swiss compulsory health insurance system perspective.